What is the maximum therapeutic dose of enoxaparin (low‑molecular‑weight heparin) for an adult patient?

Maximum Therapeutic Dose of Enoxaparin

The maximum therapeutic dose of enoxaparin is 100 mg per dose for the first two doses when used with fibrinolytic therapy in patients under 75 years of age, or 150 mg per dose as an absolute maximum in specific clinical contexts. 1

Standard Therapeutic Dosing

The standard therapeutic dose of enoxaparin is 1 mg/kg subcutaneously every 12 hours for most clinical indications including acute coronary syndromes and venous thromboembolism 1. This represents the baseline from which maximum doses are derived.

Context-Specific Maximum Doses

Acute Coronary Syndromes with Fibrinolysis

For patients under 75 years receiving fibrinolytic therapy:

• Initial IV bolus: 30 mg
• Followed by: 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for the first 2 doses) 1

For patients 75 years or older:

• No IV bolus
• 0.75 mg/kg subcutaneously every 12 hours (maximum 75 mg for the first 2 doses) 1

This age-based dose capping is critical because older patients have increased bleeding risk, and the guidelines explicitly limit the maximum dose to reduce hemorrhagic complications 2.

Absolute Maximum Single Dose

The absolute maximum single dose is 150 mg, which may be used in specific clinical scenarios, particularly in patients with extreme obesity 3. However, this represents an upper boundary rather than a routine recommendation.

Special Population Considerations

Renal Insufficiency

For patients with creatinine clearance <30 mL/min:

• Reduce to 1 mg/kg subcutaneously once daily (not twice daily) 1
• This effectively halves the total daily dose to prevent drug accumulation and bleeding complications 4

Obesity

Patients with obesity present a dosing paradox: while standard weight-based dosing (1 mg/kg) might suggest very high absolute doses, evidence shows:

• Doses are often capped at 150 mg per dose in clinical practice 3
• Doses above 1 mg/kg in patients >150 kg are associated with increased bleeding risk 5
• Many clinicians use reduced weight-based doses (0.7-1 mg/kg) in morbidly obese patients 6, 7

The 2025 ACC/AHA guidelines do not provide specific obesity-related dose caps beyond the standard recommendations, but real-world practice and safety data support caution with doses exceeding 150 mg 1, 3.

Critical Safety Considerations

Never exceed 100 mg per dose for the first two doses in the fibrinolysis setting for patients under 75 years, as this is the evidence-based maximum that balances efficacy against bleeding risk 1. The guidelines are explicit about this cap because higher doses in acute coronary syndrome trials were associated with unacceptable bleeding rates.

Do not switch between enoxaparin and unfractionated heparin during treatment, as this increases bleeding risk significantly 2.

Practical Dosing Algorithm

1. Determine indication: ACS with fibrinolysis has specific dose caps; other indications use standard 1 mg/kg dosing
2. Assess age: If ≥75 years with fibrinolysis, use 0.75 mg/kg with 75 mg cap
3. Check renal function: If CrCl <30 mL/min, switch to once-daily dosing
4. Consider weight: If >150 kg, consider capping at 150 mg per dose and monitoring anti-Xa levels
5. Apply indication-specific caps: For fibrinolysis in patients <75 years, cap first two doses at 100 mg

The evidence strongly supports these maximum doses as they represent the upper limits tested in major clinical trials, with higher doses associated with increased bleeding without additional efficacy benefit 1, 5.